labcoat1LG

bmiBMI is a leading edge, privately-held vaccine design and development company located in Frederick, Maryland, USA. For the past several years, the Company has been devoted to developing its proprietary “Immune Refocusing Technology” or “IRT” related to the dampening or enhancement of pathogen epitopes to encourage a more effective natural immune response. Recently, the Company has developed a proprietary inactivation technology aimed at developing innovative vaccines for inadequately served global health needs. These recent efforts have included developing ultra-IPV.

purplearrowBriefly, the target organisms are complexed with a manganese-decapeptide-phosphate (MDP) mixture and then exposed to UV light. A very quick, easy and reproducible process. The MDP system has been adapted from radiation-resistant bacteria such as Deinococcus radiodurans. 

The MDP-UV inactivation method is a platform technology. BMI and collaborators are applying the technology to the development of vaccines against additional important human pathogens, such as MRSA and Acinetobacter baumannii, two hard-to-treat bacteria that are resistant to multiple antibiotics.

Gregory J. Tobin, PhD

gregory tobin phdPresident and CEO. Dr. Tobin has led research and technical programs at BMI since 1999.  A vaccinologist and molecular biologist, Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; and coordination of multi-site studies.  Dr. Tobin fosters a highly interactive research and development group to apply the Company’s two proprietary technologies (Novel Inactivated Vaccines and Immune Refocusing Technology) to the design of improved vaccines. Current research projects employ the technology used in UltraIPV to the derivation of vaccines against two antibiotic-resistant bacteria, Acinetobacter baumannii and MRSA. In addition, Dr. Tobin’s work includes the use of Immune Refocusing in the design of the first vaccine against human rhinovirus (HRV) and of a broadly protective influenza vaccine.  Dr. Tobin has been the Principal Investigator or technical lead on twelve NIH grants, seven DOD research contracts, and several grants funded by other agencies or companies.

David S. Silberstein, PhD

davidsmDirector and Scientific Advisor. Dr. Silberstein received his PhD in Microbiology at Columbia University and Postdoctoral training at Harvard Med School/Brigham & Women’s Hospital.  He continued for seven years with a faculty appointment at Harvard, leading an NIH-funded research team studying the biochemistry of lung inflammation. 

This was followed by 20 years at AstraZeneca Pharmaceuticals where he had leadership roles in genomics, translational science, company-wide portfolio management, and science support for two products through launch to aggregate sales of greater than $30 billion. 

Since 2013, he has worked as an advisor and company officer with a number of early stage biotech companies and as a consultant to investment firms.

Drs. Dollery & MacLeoad

2staff

Drs. Stephen Dollery and David MacLeod discuss antiviral assays.

A. Gregory Kelly

barry cropChair, Board of Directors. Greg Kelly, M.S., M.B.A., has been an active member of Maryland’s emerging business community for over 35 years. He has invested in a number of early-stage companies, and he has founded, been a Board Member of, or been a strategic advisor and financial consultant to numerous other companies.

For 20 years, Greg served in the Health Care & Life Sciences practice of KPMG in Baltimore, where he managed or provided public and private offerings assistance, financial structuring advice , transactions services, small and large company performance improvement initiatives, and attestation services.

Greg is currently a founder, the Co-President, the Chief Science Officer and the Chief Financial Officer of Blue Ocean Biosystems, Inc. in Easton, Maryland, and the Managing Director of Acadine Ventures, LLC.

Barry Henderson, M.Sc.

barry cropDirector of Business Development. Barry holds a M.Sc. in Bacteriology & Virology and M.Sc. Molecular Pathology both from University of Manchester. He has over 20 years business development experience working with academics, businesses and clinicians to develop and progress innovative technologies to market.

He recently completed a three-year contract as Business Development Director, leading the Life Sciences sector with Invest NI’s US Office, and brings a wealth of relevant experience, having previously held roles in biomedical research, sales & marketing within the biotech sector and life science innovation management with Ulster University.

Our Scientists at Work

4staff

Scientists Steve Dollery, Taralyn Wiggins, Ruth Bushnell, and David MacLeod wrap up analyzing polio neutralization assays.

John Tobin and Claire

claire john2

John Tobin and Claire are having a discussion about important topics.

Our Company Morale Officers

doggies

Here, Claire (left) is getting pointers from our experienced, Chief Morale Officer, Vesper (right).

logo2019f2
 BMI is a innov
ative, privately-held vaccine design and development company located in Frederick, Maryland, USA.
Contact Us     Email: polio@bmi-md.com      Phone: (301) 378-2551  Info: Download White Paper
Download our recent publication in PLOS ONE describing the inactivation of polio using gamma irradiation: Click here.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok